Combination checkpoint inhibitors for treatment of non-small-cell lung cancer: an update on dual anti-CTLA-4 and anti-PD-1/PD-L1 therapies

Sonam Puri MD, Michael Shafique MD

Abstract

Immunotherapy has revolutionized cancer treatment. In non-small-cell lung cancer (NSCLC), monotherapy with immune checkpoint inhibitors has improved survival in metastatic disease. Combinations of immune checkpoint inhibitors have shown synergy in preclinical models and are being studied as part of the treatment armamentarium in NSCLC. This review discusses the rationale, outcomes, and challenges of combination immune checkpoint blockade. Despite the challenges, this paper also presents some solutions and ways to improve our understanding and implementation of such combinations in the future.

Article Details

Article Type

Review

DOI

10.7573/dic.2019-9-2

Publication Dates

Accepted: ; Published: .

Citation

Puri S, Shafique M. Combination checkpoint inhibitors for treatment of non-small-cell lung cancer: an update on dual anti-CTLA-4 and anti-PD-1/PD-L1 therapies. Drugs in Context 2020; 9: 2019-9-2. DOI: 10.7573/dic.2019-9-2

Register for alerts

I would like to be contacted by Drugs in Context when new articles are posted.